

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number  
**WO 01/14571 A1**

(51) International Patent Classification<sup>7</sup>: C12N 15/82,  
15/12, 5/10, C12P 21/02, A01H 5/00

[CA/CA]; 4, 2744 Brentwood Blvd. N.W., Calgary,  
Alberta T2L 1J4 (CA).

(21) International Application Number: PCT/CA00/00975

(74) Agent: BERESKIN & PARR; 40 King Street West, 40th  
floor, Toronto, Ontario M5H 3Y2 (CA).

(22) International Filing Date: 23 August 2000 (23.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/378,696 23 August 1999 (23.08.1999) US

(71) Applicant (for all designated States except US): SEM-  
BIOSYS GENETICS INC. [CA/CA]; 2500 University  
Drive N.W., Room 460, Calgary, Alberta T2N 1N4 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VAN ROOIJEN,  
Gijs [NL/CA]; 3223 Bears paw Drive N.W., Calgary, Al-  
berta T2L 1T1 (CA). KEON, Richard, Glenn [CA/CA];  
302, 602-2nd Avenue N.W., Calgary, Alberta T2N 0E1  
(CA). BOOTHE, Joseph [CA/CA]; 332, 6th Avenue  
N.W., Calgary, Alberta T2E 0L9 (CA). SHEN, Yin

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 01/14571 A1

(54) Title: COMMERCIAL PRODUCTION OF CHYMOSIN IN PLANTS

(57) Abstract: A method for the commercial production of chymosin which involves the recombinant expression of chymosin in plant seeds, that enables chymosin to accumulate to at least 0.5 % (w/w) of total seed protein is described. An improved method for the isolation of chymosin from the seed is also described.

- 1 -

**Title:** Commercial Production of Chymosin in Plants

**FIELD OF THE INVENTION**

The present invention relates to improved methods for the recombinant production and isolation of chymosin from plants.

5 **BACKGROUND OF THE INVENTION**

Chymosin, also known as rennin, is a commercially important enzymatic protein, commonly used in the cheese manufacturing industry to coagulate milk. Traditionally chymosin has been prepared from its natural source, the fourth stomach of unweaned calves, although recovery  
10 from the stomachs of other mammals, such as lamb, goats etc. heretofore was known. More recently, primarily as a result of a decrease in calf production, recombinant DNA techniques have been employed to produce chymosin by fermentation in genetically engineered microorganisms. Thus a variety of bacterial and fungal hosts have been genetically modified  
15 to produce chymosin by fermentation, including for example, the bacterial hosts *Escherichia coli*, (European Patent 0 134 662 A1; Nishimori *et al.* (1982) J. Biochem 91: 1085-1088.), *Bacillus subtilis* (US patent 5,624,819; 5,716,807 and Parente *et al.* (1991) FEMS 77: 243-250) and the fungal hosts *Aspergillus* sp. (European Patent 0 575 462 B1; US patents 5,364,770 and  
20 5,863,759; Cullen *et al.* (1987) Bio/Technology 5: 369-375., Dunn-Coleman *et al.* (1991) Bio/Technology 9: 976-981., and Tsuchiua *et al.* (1993) Appl. Microbial Biotech. 40: 327-332), *Kluyveromyces lactis* (van der Berg *et al.* (1990) Bio/Technology 8: 135-139 and *Trichoderma reesei* (Jarkki *et al.* (1989) Bio/Technology 7: 596-603; Pitts *et al.* (1991) Biochemical Society  
25 Transactions 19: 663-665). As well, more general expression in fungi, yeast and bacteria (US Patents 4,666,847) and in filamentous fungi (US patent 5,578,463).

The active enzyme chymosin (E.C. 3.4.23.4) is comprised of a polypeptide chain of a molecular mass of 35.6 kDa. However crude extracts  
30 of calf stomach mucosa in addition to active chymosin, contain two inactive precursor polypeptides known as pre-pro-chymosin and pro-chymosin. Pre-pro-chymosin contains an extra 58 amino acids at the

- 2 -

N-terminus, whereas pro-chymosin contains an extra 42 amino acids. Conversion of the inactive precursor protein into enzymatically active chymosin requires the step-wise removal of the chymosin pre-peptide and pro-peptide. *In vivo* these activation steps take place in the calf stomach.

5 The chymosin pre-peptide directs secretion of the polypeptide by the stomach cells and is removed upon secretion of the polypeptide by the stomach cells. The chymosin pro-peptide is subsequently removed in the gastric lumen, thereby activating the enzyme. The activation reaction can also be performed *in vitro* at pH values below 5. With regards to the

10 enzyme chymosin, it should further be noted that chymosin purified from calf stomach is a mixture of two different polypeptides known as chymosin A and chymosin B. Both of these polypeptides are active and differ only with respect to one amino acid. The amino acid residue at position #290 is an aspartate residue in chymosin A and a glycine residue in chymosin B

15 (Foltman *et al.*, (1977) Proc. Natl. Acad. Sci. USA 74: 2331-2324; Foltman *et al.*, (1979) J. Biol. Chem. 254: 8447-8456).

There are several disadvantages associated with the recombinant production of chymosin in fermentation systems. In general, fermentation systems require the use of large fermentation vessels that

20 have both large space and energy requirements and consequently are costly. As well, the growth media require large volumes of water and may require special chemicals. Both of these may present environmental issues in the disposal of the large amounts of potentially harmful waste. Further, storage and shipment of raw material containing chymosin is

25 problematic. The bacterial or fungal fermentation broth need to be processed immediately or refrigerated in large volumes since the enzyme is not stable for long periods in the broth.

The use of plants as bioreactors for the commercial production of recombinant proteins is well known. For example, avidin,

30  $\beta$ -glucuronidase and aprotinin (see patents US Patents 5,767,379, 5,804,694 and 5,824,870) have been recombinantly expressed in corn. Further, US Patents 5,543,576 and 5,714,474 are broadly directed to the recombinant

- 3 -

production of enzymes in seeds and to the use of seeds or milled seeds comprising enzymes as a raw material in the preparation of food and feed products. Although US Patents 5,543,576 and 5,714,474 suggest chymosin as one potential enzyme that may be produced in seeds, there is no  
5 reduction to practice. These patents are further limited by the fact that in order to use the chymosin for the commercial production of cheese, chymosin would have to be purified from the seed or milled seeds.

PCT patent application WO 92/01042 discloses the expression of chymosin in the leaves of transgenic tobacco and potato plants. According  
10 to the disclosure chymosin expression levels of only 0.1% to 0.5% (w/w) of total soluble leaf protein were attained. The methodology of WO 92/01042 is further limited in that the production in leaves would require immediate extraction of the enzyme from the leaf material upon harvesting of the plants as the enzyme would lose activity when stored in  
15 leaves. In addition, due to the relatively high water content of leaves, large amounts of biomass must be processed.

There is a need in the art to further improve methods for the recombinant expression of chymosin in plants.

#### SUMMARY OF THE INVENTION

20 The present invention relates to novel and improved methods of producing commercial levels of chymosin in transgenic plants. The inventors have found that chymosin when expressed in the seeds of transgenic plants accumulates to levels of at least 0.5% (w/w) of total seed protein.

25 Accordingly, the invention provides a method for the production of chymosin in a plant seed comprising:

a) introducing into a plant cell a chimeric nucleic acid sequence molecule comprising in the 5' to 3' direction of transcription:

- 30 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
- 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;

- 4 -

3) a third nucleic acid sequence capable of terminating transcription in said plant cell;

b) growing said plant cell into a mature plant capable of setting seed; and

5 c) obtaining seed from the mature plant wherein said seed contains chymosin.

Preferably, at least 0.5% (w/w) of the total seed protein is chymosin.

The present invention also provides a method for the  
10 production of plant seeds containing at least 0.5% (w/w) chymosin in the total seed protein comprising:

(a) introducing into each of at least two plant cells a chimeric nucleic acid sequence molecule comprising in the 5' to 3' direction of transcription:

- 15 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
- 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
- 20 3) a third nucleic acid sequence capable of terminating transcription in said plant cell;

(b) growing each plant cell into a mature plant capable of setting seed;

(c) obtaining seed from each mature plant;

(d) detecting the levels of chymosin in the seed of each plant  
25 obtained in step (c) or in the seed of a plant generated from the seed of a plant obtained in step (c); and

(e) selecting plants that contain at least 0.5% (w/w) chymosin in the total seed protein.

In preferred methods of the present invention, the nucleic acid  
30 sequence capable of regulating transcription is a seed-specific promoter. In further preferred methods, the chimeric nucleic acid sequence additionally comprises a signal sequence capable of targeting the chymosin polypeptide

- 5 -

to the plant apoplast. In further preferred methods, the nucleic acid sequence encoding chymosin sequence is optimized for plant codon usage and the chymosin sequence further contains the chymosin pro-peptide or pre-pro-peptide or pre-peptide sequences.

5 In a further aspect, the present invention provides plant seeds expressing chymosin. In a preferred embodiment of the present invention, the plant seeds comprise a chimeric nucleic acid sequence comprising in the 5' to 3' direction of transcription:

- 10 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
- 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
- 15 3) a third nucleic acid sequence capable of terminating transcription in said plant cell wherein the seed contains chymosin.

Preferably, at least 0.5% (w/w) of the total seed protein is chymosin.

In another aspect the present invention provides plants capable of setting seed expressing chymosin. In a preferred embodiment of the invention, the plants capable of setting seed comprise a chimeric nucleic acid sequence comprising in the 5' to 3' direction of transcription:

- 25 1) a first nucleic acid sequence capable of regulating transcription in a plant cell operatively linked to;
- 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
- 3) a third nucleic acid sequence capable of terminating transcription in said plant cell, wherein the seed contains chymosin.

In yet another aspect the present invention provides a method  
30 for recovering chymosin from plant seeds. Accordingly, the present invention provides a method for obtaining chymosin from a plant seed comprising:

- 6 -

- a) introducing into a plant cell a chimeric nucleic acid sequence molecule comprising in the 5' to 3' direction of transcription:
- 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
  - 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
  - 3) a third nucleic acid sequence capable of terminating transcription in said plant cell;
- b) growing said plant cell into a mature plant capable of setting seed;
- c) obtaining seed from the mature plant wherein said seed contains chymosin; and
- d) isolating said chymosin from said seed.
- In preferred embodiments, isolation of chymosin from seed in step (d) comprises:
- (i) crushing of the plant seed to obtain crushed plant seed;
  - (ii) contacting the crushed plant seed or a fraction thereof with a protein binding resin; and
  - (iii) recovering the chymosin from the protein binding resin.
- In further preferred embodiments upon crushing of the plant seed the crushed seed material is fractionated into (a) an aqueous phase containing substantially all of the chymosin, (b) an oil fraction, and (c) a fraction containing the insoluble material insoluble material. Accordingly step (d) more preferably comprises:
- (i) crushing of the plant seed to obtain crushed plant seed;
  - (ii) fractionating the crushed plant seed into an oil fraction, aqueous fraction and a fraction comprising insoluble material;
  - (iii) contacting the aqueous fraction with a protein binding resin; and
  - (iv) recovering the chymosin from the protein binding resin.

- 7 -

In a preferred embodiment, the protein binding resin is a hydrophobic interaction resin. In further preferred embodiments of the invention, the isolation of the chymosin further comprises the employment of an ion exchange resin and a hydrophobic interaction resin.

5 Other features and advantages of the present invention will become readily apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications  
10 within the spirit and scope of the invention will become apparent to those skilled in the art of this detailed description.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

The invention will now be described in relation to the drawings in which:

15 Figure 1 shows the nucleotide sequence (SEQ.ID.NO.:1) and corresponding amino acid sequence (SEQ.ID.NO.:2) of the open reading frame of a pre-pro-chymosin sequence. The "pre" sequence is indicated in Italics between and including amino acids 1 to 26. The "pre" sequence encodes a signal sequence identical to the PR-S signal sequence from  
20 tobacco sequence (Sijmons *et al.* (1990) Bio/technology 8: 217-221). Amino acids 27 to 67 inclusive are the "pro" sequence with the remaining amino acids encoding the mature chymosin polypeptide.

Figure 2 shows the nucleotide sequence (SEQ.ID.NO.:3) of the phaseolin promoter- a pre-pro-chymosin-phaseolin terminator sequence  
25 responsible for the high levels of expression of chymosin in plant seeds.

Figure 3 is a Western blot analysis comparing a chymosin standard and a protein extract of seeds from a *Brassica* plant expressing chymosin.

Figure 4 is a bar diagram showing the expression of chymosin  
30 in flax seeds derived from independent transformed flax plants.



- 8 -

Figure 5 shows a SDS-polyacrylamide gel showing progressive purification of chymosin obtained from transgenic seeds of *Brassica napus* as described in example 5.

#### DETAILED DESCRIPTION OF THE INVENTION

5           As hereinbefore mentioned, the present invention relates to improved methods for the production of chymosin in transgenic plants. The present inventors have surprisingly found that by expressing chymosin in the seeds of plants, chymosin accumulation levels exceeding 0.5% (w/w) of total seed protein may be attained. These high expression  
10 levels in plant seeds allow significant commercial savings since the acreage of plants that needs to be grown can be limited and the amount of biomass that must to be subjected to extraction is reduced. The amount of biomass processed is further limited due to the relatively low water content present in plant seed. Furthermore, the expression in plants seed  
15 offers flexibility in storage and shipment of chymosin as a raw material, since chymosin retains its enzymatic activity upon extraction from stored seed.

Accordingly, the invention provides a method for producing chymosin in plant seeds comprising:

- 20           a) introducing into a plant cell a chimeric nucleic acid sequence molecule comprising in the 5' to 3' direction of transcription:
- 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
  - 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
  - 25 3) a third nucleic acid sequence capable of terminating transcription in said plant cell;
- b) growing said plant cell into a mature plant capable of setting seed; and
- 30           c) obtaining said seed from said mature plant wherein the seed contains chymosin.

- 9 -

In a preferred embodiment, at least 0.5% (w/w) of the total seed protein is chymosin. More preferably at least 1% (w/w) of the total seed protein is chymosin, even more preferably at least 2% (w/w) of the total seed protein is chymosin and most preferably at least 4% (w/w) of the total seed protein is chymosin.

As used herein the term "chymosin polypeptide" refers to all chymosins and includes pre-pro-chymosin and pro-chymosin polypeptides. The chymosin is preferably mammalian such as bovine, goat and sheep chymosin.

The term "nucleic acid sequence encoding a chymosin polypeptide" refers to all nucleic acid sequence encoding chymosin and all nucleic acid sequences that hybridize thereto under stringent hybridization conditions or would hybridize thereto but for the use of synonymous codons.

Appropriate "stringent hybridization conditions" which promote DNA hybridization are known to those skilled in the art, or may be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the following may be employed: 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C. The stringency may be selected based on the conditions used in the wash step. For example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

The term "nucleic acid sequence encoding a chymosin polypeptide" includes nucleic sequences that encode pre-pro-chymosin and pro-chymosin. In addition, the nucleic acid sequences that encode chymosin may be linked to additional nucleic acid sequences such as those that encode signal peptides.

In preferred embodiments of the present invention, nucleic acid sequences encoding bovine chymosin A or chymosin B are used (Moir et al. (1982) Gene 19: 127-138.; Harris et al. (1982) Nucleic Acids Res. 10:

- 10 -

2177-2187). In further preferred embodiments nucleic acid sequences encoding chymosin are used which have been optimized for codon usage in plants. The natural bovine chymosin sequence has a GC content of 56% with a preference for a G or C in the third position of the codon. This  
5 differs from the codon bias for cattle which has an average GC content of 39% (Mishimori et al. (1982) J Biochem 91: 1085-1088). In a preferred embodiment, the codon usage of chymosin is manipulated to reflect a codon usage typical of seed-storage proteins found in oilseeds, for example using a GC content of 49% with a preference for a G or C in the third  
10 position of the codon (see Example 1).

The invention further includes the use of nucleic acid sequences encoding chymosin precursor proteins that can be activated, for example by treating the precursor polypeptide at low pH, to exhibit chymosin activity. Nucleic acid sequences encoding chymosin precursor  
15 proteins that may be used in accordance with the present invention include naturally occurring nucleic acid sequences encoding chymosin precursor proteins, such as "pro-chymosin", "pre-chymosin" and "pre-pro-chymosin", as well as non-naturally occurring nucleic acid sequences encoding precursor proteins comprising chymosin and capable  
20 of activation to exhibit chymosin activity. In a preferred embodiment of the invention, a nucleic acid sequence encoding bovine pro-chymosin comprising 42 extra amino acid residues is used (Moir et al. (1982) Gene 19: 127-138.; Harris et al. (1982) Nucleic Acids Res.10: 2177-2187). Other nucleic acid sequences encoding precursor proteins that may be used in accordance  
25 with the present invention include those encoding bovine pre-pro-chymosin comprising 58 extra amino acid residues (Moir et al. (1982) Gene 19: 127-138.; Harris et al. (1982) Nucleic Acids Res.10: 2177-2187), and nucleic acid sequences encoding plant signal sequences capable of targeting chymosin to a preferred subcellular compartment, for  
30 example the plant apoplast, the golgi apparatus or cytoplasm. In one preferred embodiment, the nucleic acid sequence encoding chymosin comprises a nucleic acid sequence encoding the tobacco pathogenesis

- 11 -

related protein-S (PR-S) signal sequence (Sijmons et al. (1990) Bio/technology 8: 217-221.) directing targeting to the plant apoplast linked to a nucleic acid sequence encoding a bovine pro-chymosin polypeptide sequence (Figure 1 and SEQ.ID.1). Other naturally occurring signal  
5 sequences that could be used in accordance with the present invention include for example the barley alpha amylase signal sequence (Rogers (1985) J. Biol. Chem. 260(6): 3731-3738) directing targeting of the chymosin sequence to the apoplast. The nucleic acid sequences encoding additional peptide sequences may be homologous as well as heterologous with  
10 respect to the nucleic acid sequence encoding the chymosin polypeptide. The nucleic acid sequence encoding the additional peptide sequences, such as the pro-peptide, pre-pro-peptide or pre-peptide, may vary in length and are preferably codon-optimized for use in plants.

In embodiments of the invention involving the activation of a  
15 chymosin precursor protein, the activation reaction may be performed upon obtaining the plant seeds by for example treating an extracted seed fraction at low pH, preferably at pH values lower than 5, or the activation reaction may take place *in planta*. It is also possible to complete the activation reaction in a mixture comprising chymosin precursor  
20 polypeptides and enzymatically active chymosin. The chymosin precursor protein may be partially active or exhibiting no chymosin activity, however the precursor protein is typically not fully active.

Nucleic acid sequences encoding chymosin are readily available or obtainable by the skilled artisan based on chymosin nucleic acid  
25 sequences and/or amino acid sequences known in the art. The bovine nucleic acid and amino acid sequences for chymosin A and chymosin B for example, are known and may be directly used in accordance with the present invention. As well, the complete primary structure of lamb preprochymosin has been deduced from cDNA (Pungercar et al. (1990)  
30 Nucleic Acids Res. 18(15): 4602). These known chymosin nucleic acid sequences may also be used to design and construct probes to identify previously undiscovered nucleic acid sequences encoding chymosin.

- 12 -

These probes may be used to isolate nucleic acid sequence encoding chymosin from for example cDNA or genomic libraries. The nucleic acid sequence encoding chymosin is preferably obtained from a mammal. Thus additional nucleic acid sequence chymosin sequences may be  
5 discovered and used in accordance with the present invention.

The term "nucleic acid sequence" as used herein refers to a sequence of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally  
10 occurring monomers or portions thereof, which function similarly. The nucleic acid sequences of the present invention may be ribonucleic (RNA) or deoxyribonucleic acids (DNA) and may contain naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The sequences may also contain modified bases such as xanthine,  
15 hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl, and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-amino adenine, 8-thiol adenine, 8-thio-alkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol  
20 guanine, 8-thioalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.

In accordance with the present invention, the chimeric nucleic acid sequences can be incorporated in a known manner in a recombinant  
25 expression vector which ensures good expression in a plant seed. Accordingly, the present invention includes a recombinant expression vector comprising a chimeric nucleic acid sequence of the present invention suitable for expression in a seed cell.

The term "suitable for expression in a seed cell" means that the  
30 recombinant expression vectors contain the chimeric nucleic acids sequence of the invention, a regulatory region and a termination region, selected on the basis of the seed cell to be used for expression, which is

- 13 -

operatively linked to the nucleic acid sequence encoding the polypeptide of desirable amino acid composition. Operatively linked is intended to mean that the chimeric nucleic acid sequence encoding the polypeptide is linked to a regulatory sequence and termination region which allows expression in the seed cell. A typical construct consists, in the 5' to 3' direction of a regulatory region complete with a promoter capable of directing expression in a plant, a chymosin coding region and a transcription termination region functional in plant cells. These constructs may be prepared in accordance with methodology well known to those of skill in the art of molecular biology (see for example: Sambrook et al. (1990) Molecular Cloning, 2nd ed. Cold Spring Harbor Press). The preparation of constructs may involve techniques such as restriction digestion, ligation, gel electrophoresis, DNA sequencing and PCR. A wide variety of cloning vectors are available to perform the necessary cloning steps. Especially suitable for this purpose are the cloning vectors with a replication system that is functional in *Escherichia coli* such as pBR322, the pUC series M13mp series, pACYC184, pBluescript etc. The nucleic acid sequence may be introduced into these vectors and the vectors may be used to transform *E. coli* which may be grown in an appropriate medium. Plasmids may be recovered from the cells upon harvesting and lysing the cells. Final constructs may be introduced into plant vectors compatible with integration into the plant such as the Ti and Ri plasmids.

The selection of regulatory sequences will determine the plant organ in which the protein is expressed and may influence the level that a gene will be transcribed. Regulatory sequences are art-recognized and are selected to direct expression in the plant cell. Accordingly, the term "regulatory sequence" includes promoters, enhancers, ribosome binding sites, introns and other expression elements. Examples of promoters include both non-seed specific, constitutive promoters such as the 35-S CaMV promoter (Rothstein et al. (1987) Gene 53: 153-161) and seed specific promoters such as the phaseolin promoter (Sengupta-Gopalan et al., (1985) PNAS USA 82: 3320-3324) or the *Arabidopsis* 18 kDa oleosin promoter

- 14 -

(van Rooijen et al., (1992) Plant Mol. Biol. 18: 1177-1179). In preferred embodiments of the present invention, seed specific promoters are employed and more specifically the phaseolin promoter. Enhancers which may be used include the AMV leader (Jobling and Gehrke (1987) Nature 5 325: 622-625) to increase the expression levels. It should be understood that the design of the expression vector may depend on such factors as the choice of the plant species and/or the type of polypeptide to be expressed.

The region containing the transcriptional terminator sequence preferably includes from about 200 to about 1,000 nucleotide base pairs and 10 may comprise any such sequences functional in plants, such as the nopaline synthase termination region (Bevan et al., (1983) Nucl. Acid. Res. 11: 369-385), the phaseolin terminator (Van der Geest et al., (1994) Plant J. 6(3): 413-423), the terminator for the octopine synthase gene of *Agrobacterium tumefaciens* or other similarly functioning elements. 15 These transcription terminator regions can be obtained as described by An (1987) Methods in Enzym. 153: 292 or are already present in plasmids available from commercial sources such as ClonTech, Palo Alto, California. The choice of the appropriate terminator may have an effect of the rate of transcription. In preferred embodiments of the invention the 20 phaseolin terminator is employed.

The expression vectors may also contain a marker gene. Marker genes comprise all genes that enable distinction of transformed plant cells from non-transformed cells, including selectable and screenable marker genes. Conveniently, a marker may be a resistance marker to a 25 herbicide, for example, glyphosate or phosphinothricin, or to an antibiotic such as kanamycin, G418, bleomycin, hygromycin, chloramphenicol and the like, which confer a trait that can be selected for by chemical means. Resistance markers to a herbicide when linked in close proximity to the chymosin gene may be used to maintain selection pressure on a 30 population of transgenic plants for those plants that have not lost the gene of interest. Screenable markers may be employed to identify transformants through observation. They include but are not limited to the

beta-glucuronidase or *uidA* gene, a beta-lactamase gene or a green fluorescent protein (Niedz et al. (1995) Plant Cell Rep. 14: 403).

A variety of techniques are available for the introduction of nucleic acid sequences, in particular DNA, into plant host cells. For example, the chimeric DNA constructs may be introduced into host cells obtained from dicotyledonous plants, such as tobacco, and oleaginous species, such as *Brassica napus* using standard *Agrobacterium* vectors by a transformation protocol such as described by Moloney et al. (1989) Plant Cell Rep. 8: 238-242 or Hinchee et al. (1988) Bio/Technol. 6: 915-922; or other techniques known to those skilled in the art. For example, the use of T-DNA for transformation of plant cells has received extensive study and is amply described in EP 0 120 516, Hoekema et al., (1985), Chapter V In: The Binary Plant Vector System Offset-drukkerij Kanters BV, Alblasterdam); Knauf et al. (1983), Genetic Analysis of Host Expression by *Agrobacterium*, p. 245, In: Molecular Genetics of Bacteria-Plant Interaction, Puhler, A. ed. Springer-Verlag, NY); and An et al., (1985) EMBO J., 4: 277-284. *Agrobacterium* transformation may also be used to transform monocot plant species (US Patent 5,591,616).

Conveniently, explants may be cultivated with *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* to allow for the transfer of the transcription construct in the plant host cell. Following transformation using *Agrobacterium* the plant cells are dispersed into an appropriate medium for selection, subsequently callus, shoots and eventually plants are recovered. The *Agrobacterium* host will harbour a plasmid comprising the *vir* genes necessary for transfer of the T-DNA to plant cells. For injection and electroporation (see below) disarmed Ti-plasmids (lacking the tumour genes, particularly the T-DNA region) may be introduced into the plant cell.

The use of non-*Agrobacterium* techniques permits the use of constructs described herein to obtain transformation and expression in a wide variety of monocotyledonous and dicotyledonous plant species. These techniques are especially useful for transformation of plant species



- 16 -

that are intractable in an *Agrobacterium* transformation system. Other techniques for gene transfer include particle bombardment (Sanford, (1988) Trends in Biotechn. 6: 299-302), electroporation (Fromm et al., (1985) PNAS USA, 82: 5824-5828; Riggs and Bates, (1986) PNAS USA 83: 5602-5606), PEG mediated DNA uptake (Potrykus et al., (1985) Mol. Gen. Genetics., 199: 169-177), microinjection (Reich et al., Bio/Techn. (1986) 4:1001-1004) and silicone carbide whiskers (Kaepler et al. (1990) Plant Cell Rep. 9: 415-418).

In a specific application such as to *B. napus*, the host cells targeted to receive recombinant DNA constructs typically will be derived from cotyledonary petioles as described by Moloney et al. (1989) Plant Cell Rep. 8: 238-242. Other examples using commercial oil seeds include cotyledon transformation in soybean explants (Hinchee et al., (1988) Bio/Technol. 6: 915-922 and stem transformation of cotton (Umbeck et al., (1987) Bio/Technol. 5: 263-266).

Following transformation, the cells, for example as leaf discs, are grown in selective medium. Once the shoots begin to emerge, they are excised and placed onto rooting medium. After sufficient roots have formed, the plants are transferred to soil. Putative transformed plants are then tested for presence of a marker. Southern blotting may be performed on genomic DNA using an appropriate probe, to show integration into the genome of the host cell.

Transformed plants grown in accordance with conventional agricultural practices, are allowed to set seed. See, for example, McCormick et al. (1986) Plant Cell Reports 5: 81-84. The chymosin expression level that is attained in accordance with the present invention, is generally expected to vary somewhat depending on the transformed plant that is assayed. As hereinbefore mentioned for the process to be economically attractive, a minimum expression level is required. The terms "commercial" and "commercial levels" as used herein denote an expression level wherein at least 0.5% (w/w) and more preferably more than 2% (w/w) and most preferably more than 4% (w/w) of total seed protein is chymosin. Preferably expression levels are determined using quantitative Western

- 17 -

blotting using the methodology described in detail in Example 2. Accordingly, typically a variety of transformed plants are screened and the expression level of chymosin in seed is determined. It is expected that typically between 5 and 50 plants may need to be screened to identify at least one plant expressing commercial levels of chymosin. Seeds obtained from plants expressing commercial levels of chymosin (i.e. at least 0.5% (w/w) of the total seed protein) are selected for further propagation.

Accordingly, the present invention provides a method for the production of plant seeds containing at least 0.5% ((w/w) chymosin in the total seed protein comprising:

- (a) introducing into each of at least two plant cells a chimeric nucleic acid sequence molecule comprising in the 5' to 3' direction of transcription:
  - 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
  - 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
  - 3) a third nucleic acid sequence capable of terminating transcription in said plant cell;
- (b) growing each plant cell into a mature plant capable of setting seed;
- (c) obtaining seed from each mature plant;
- (d) detecting the levels of chymosin in the seed of each plant obtained in step (c) or in the seed of a plant generated from the seed of a plant obtained in step (c); and
- (e) selecting plants that contain at least 0.5% (w/w) chymosin in the total seed protein.

Chymosin activity can be assayed by spectrophotometric or fluorometric methods or by milk-clotting assays. In the milk-clotting assay, a diluted sample is added to a milk solution so that the final solution contains 8% skim milk and 0.05%  $\text{CaCl}_2$  in water. The clotting time or flake point is measured as the time it takes for the thin film of

- 18 -

milk to break into visible particles. The concentration of chymosin is determined by comparing to a linear standard plotted as clotting time in seconds against the chymosin concentration (Tsuchiya et al. (1993) Appl. Microbiol. Biotechnol. 40: 327-332).

- 5 Two or more generations of plants may be grown and either crossed or selfed to allow identification of plants and strains with desired phenotypic characteristics including production of the recombinant polypeptide. It may be desirable to ensure homozygosity in the plants to assure continued inheritance of the recombinant trait. Methods for  
10 selecting homozygous plants are well known to those skilled in the art of plant breeding and include recurrent selfing and selection and anther and microspore culture. Homozygous plants may also be obtained by transformation of haploid cells or tissues followed by regeneration of haploid plantlets subsequently converted to diploid plants by any number  
15 of known means (e.g. treatment with colchicine or other microtubule disrupting agents).

The present invention also provides plant seeds expressing chymosin. In a preferred embodiment of the present invention the plant seeds comprise a chimeric nucleic acid sequence comprising in the 5' to 3'  
20 direction of transcription:

- 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
- 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
- 25 3) a third nucleic acid sequence capable of terminating transcription in said plant cell, wherein the seed contains chymosin.

In a further aspect the present invention provides plants capable of setting seed expressing chymosin. In a preferred embodiment of  
30 the invention, the plants capable of setting seed comprise a chimeric nucleic acid sequence comprising in the 5' to 3' direction of transcription:

- 19 -

- 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
- 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
- 5 3) a third nucleic acid sequence capable of terminating transcription in said plant cell, wherein the seed contains chymosin.

The methods disclosed in the present invention can be used over a broad range of plant species. Particularly preferred plant cells employed in accordance with the present invention include cells from the following plants: soybean (*Glycine max*), rapeseed (*Brassica napus*, *Brassica campestris*), sunflower (*Helianthus annuus*), cotton (*Gossypium hirsutum*), corn (*Zea mays*), tobacco (*Nicotiana tabacum*), alfalfa (*Medicago sativa*), wheat (*Triticum sp.*), barley (*Hordeum vulgare*), oats 15 (*Avena sativa* L.), sorghum (*Sorghum bicolor*), Arabidopsis thaliana, potato (*Solanum sp.*), flax/linseed (*Linum usitatissimum*), safflower (*Carthamus tinctorius*), oil palm (*Eleais guineensis*), groundnut (*Arachis hypogaea*), Brazil nut (*Bertholletia excelsa*) coconut (*Cocus nucifera*), castor (*Ricinus communis*), coriander (*Coriandrum sativum*), squash (*Cucurbita maxima*), jojoba (*Simmondsia chinensis*) and rice (*Oryza sativa*). 20

The invention also provides a method for recovering chymosin from a plant seed comprising:

- a) introducing into a plant cell a chimeric nucleic acid sequence molecule comprising in the 5' to 3' direction of transcription:
  - 25 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
  - 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
  - 3) a third nucleic acid sequence capable of terminating transcription in said plant cell;
- 30 b) growing said plant cell into a mature plant capable of setting seed;

- 20 -

c) obtaining seed from the mature plant wherein said seed contains chymosin; and

d) isolating said chymosin from said seed.

In preferred embodiments, isolation of chymosin from seed  
5 comprises:

- i) crushing the plant seed to obtain crushed plant seed;
- ii) contacting the crushed plant seed or a fraction thereof with a protein binding resin; and
- iii) recovering chymosin from the protein binding resin.

10 The term "crushing" as used herein refers to any process or methodology to comminute seed and includes mechanical pressing, grinding, crushing processes and the like. Preferably the seeds are ground using a mill such as for example a colloid mill, a disk mill, a pin mill, an orbital mill, an IKA mill, a homogenizer or similar equipment. The  
15 selection of the crushing equipment depends inter alia on the throughput requirements and on the seed source. Typically the crushing conditions selected result in the breakage of individual seed cells. It is of importance however that the chymosin polypeptide remains intact. Crushing conditions that would substantially inactivate the enzyme are undesirable  
20 in the practice of the present invention. The crushing process practiced in accordance with the present invention permits the recovery of a crushed plants seeds comprising chymosin.

The crushing process may be carried out using dry seed. Preferably however the seeds are crushed in the presence of water or a  
25 buffer. Prior to, during or after the crushing process, additional water or a buffer may be employed to dilute the seed extract. Preferably the crushed seed fraction obtained is between 2 and 100 fold diluted relative to the original seed volume. Furthermore the salt concentration may be adjusted by the addition of extraneous salts or salt solutions to the crushed  
30 seeds. Accordingly, preferably the extraneous salt concentration of the crushed seed that is obtained is preferably between approximately 0.1M and 2M. Suitable salts to adjust the salt concentration in accordance with the

- 21 -

present invention include sulfate salts for example sodium sulfate, magnesium sulfate, and ammonium sulfate; phosphate salts, for example sodium phosphate, magnesium phosphate and ammonium phosphate; chloride salts, for example sodium chloride and calcium chloride; and mixtures thereof. A preferred salt used in accordance with the present invention is sodium chloride.

Upon crushing of the seed it is generally preferable to prepare an aqueous fraction of the crushed plant seeds by the removal of the insoluble material and the oil fraction of the seed. The insoluble material is substantially insoluble or in an insolublized association with insoluble material produced upon crushing of the plant seed material. The insoluble material is either produced in the plant seed or may be associated with the plant seed in the form of insoluble aggregates including, seed hulls, fibrous material, carbohydrates or external contaminants such as soil particles and the like. The process permits the separation of soluble seed material from insoluble seed material. Any suitable methodology may use be accomplished using any methodology that allows the separation of the seed insoluble material from the soluble seed constituents, including for example gravitation based methods such as for example centrifugation or size exclusion based methods such as filtration. In a preferred embodiment of the present invention centrifugation is used. Centrifugation equipment that may be used in accordance with the present invention includes a tubular bowl centrifuge, a decantation centrifuge, a hydrocyclone, a disk stack centrifuge, and the like.

Removal of the oil fraction is particularly desirable when chymosin is produced in seeds comprising a relatively high oil content such as rapeseed, flax, sunflower seed and the like. Any suitable methodology may be used that allows the separation of the oil fraction from the aqueous fraction of the seed, including for example gravitation based methods such as for example centrifugation or size exclusion based methods such as filtration. In a preferred embodiment of the present invention centrifugation is used. Centrifugation equipment that may be

- 22 -

used in accordance with the present invention includes a tubular bowl centrifuge, a decantation centrifuge, a hydrocyclone, a disk stack centrifuge, and the like.

Generally the solids are removed prior to the oil fraction,  
5 however in other embodiments of the invention the removal of insoluble seed constituents and the oil fraction is accomplished concomitantly using a gravity based method such as a 3-phase tubular bowl centrifuge or decanter or a size-exclusion based separation method.

In a further preferred embodiment selective precipitation of  
10 the crushed plant seed extract or fraction thereof may be performed prior to contacting the plant seed extract or fraction thereof with the protein binding resin. This selective precipitation step is preferably accomplished by selecting any conditions that allow the precipitation of at least 50% (w/w) of the endogenous seed proteins while substantially all chymosin  
15 remains soluble. With the term "substantially all" it is meant that at least approximately 75% (w/w) of all chymosin remains soluble. In a more preferred embodiment at least 85% (w/w) of all chymosin remains soluble. In the most preferred embodiment at least approximately 90% (w/w) of all chymosin remains soluble. In preferred embodiments of the present  
20 invention precipitation is accomplished by adjusting the pH of the crushed seed extract. The pH of the crushed seed is preferably adjusted to a pH of less than approximately 5.5. More preferably the pH is adjusted to a pH of between approximately 1.5 and 3.5. Most preferably the pH is adjusted to a pH of approximately 2.0. Any suitable acid may be used to adjust the pH,  
25 such as hydrochloric acid, sulfuric acid, phosphoric acid and the like preferably having a pH of less than 2. The precipitation step may take place concomitantly with the crushing step. In preferred embodiments, the precipitation step is performed subsequent to the seed-crushing step. Furthermore the precipitation may be performed prior to or subsequent to  
30 either the removal of the insoluble material or removal of the oil fraction. It is preferred however to remove the insoluble material and the oil fraction prior to selective precipitation.

The term "protein binding resin" means any resin that is capable of binding to proteins, in particular chymosin. In a preferred embodiment, the protein binding resin is a hydrophobic interaction resin.

The present inventors have found that a hydrophobic interaction resin is particularly useful in isolating chymosin from plant seeds. A "hydrophobic interaction resin" refers to any protein compatible resin capable of differentially binding proteins present in a mixture of proteins, said differential binding occurring as a result of differences in hydrophobic characteristics of the proteins present in the mixture.

Hydrophobic interaction resins are generally art-recognized and include for example sepharose resins having functional groups such as alkyl groups (e.g. butyl-sepharose, octyl-sepharose) and phenyl groups (e.g. phenyl-sepharose) and superose resins having functional groups such as alkyl groups and phenyl groups. The hydrophobic interaction resin may be used batch-wise or prepared for column chromatography.

In the practice of the present invention the crushed seed extract or a fraction thereof comprising chymosin is contacted with the hydrophobic interaction resin under conditions that will permit chymosin to bind to the hydrophobic interaction resin. Preferred binding conditions in accordance with the present invention are conditions of high ionic strength, for example 1M to 2M salt concentrations, e.g. 1.5M ammonium sulphate. Other salts that may be used in accordance with the present invention include sulfate salts for example magnesium sulfate; phosphate salts, for example sodium phosphate, magnesium phosphate and ammonium phosphate; chloride salts, for example sodium chloride and calcium chloride; and mixtures thereof. Once binding has been accomplished conditions are altered so that the bound substances are eluted differentially thus allowing the recovery of chymosin from the hydrophobic interaction column. Preferably the ionic strength is altered to accomplish elution, for example the ionic strength is reduced from 1.5 M to 0.5 M. The changes in conditions may be performed stepwise or gradually. Other elution methodologies that may be employed include



- 24 -

reducing the eluent polarity for example using a glycol gradient up to 50%, adding chaotropic species such as urea, guanidine hydrochloride; the addition of detergents; changing pH or temperature.

In further preferred embodiments, chymosin is additionally  
5 purified by employing an ion exchange resin. An "ion exchange resin" refers to any protein compatible resinous material which is capable of binding charged compounds. Ion exchange columns are art recognized and include anion and cation exchange resins. These resins may be employed in a batch fashion or as a column. Preferred cation exchange  
10 columns for use in the present invention, include for example Pharmacia SP-Sephadex, Indion SP-2, IBF SP-Triacryl, IBF SP-Spherodex and the like. Preferred anion exchange resins in this regard are DEAE cellulose, IBF Q Spherodex, Pharmacia Q-Sephadex, Indion Q-2, IBF Q-Trisacryl and the like. In the practice of the present invention the aqueous solution of  
15 comprising chymosin is contacted with the ion-exchange resin under conditions at which the chymosin will bind to the resin. Whether chymosin binds to the resin depends on the pH of the aqueous solution, i.e. whether the pH is below or above the isoelectric point of chymosin (approximately 4.6). Accordingly, contacting the aqueous solution  
20 comprising chymosin under conditions at which chymosin will bind to the column refers to adjusting the pH of the solution above or below its isoelectric point so that it will bind to the selected resin. Binding of chymosin to the resin further depends on the ionic strength. Accordingly, the salt concentration may vary, for example a concentration of less than  
25 250mM NaCl may be used. In order to elute chymosin of the resin conditions are selected which permit the elution of chymosin from the resin, preferably the ion concentration is adjusted to elute the chymosin of the resin. For example the salt concentration may be adjusted to a concentration of 2M NaCl. The pH and salt concentration of the chymosin  
30 preparation thus recovered may be adjusted as desired. The ion exchange resin step may be employed either prior or after the hydrophobic interaction step.

- 25 -

Optionally the chymosin preparation may be concentrated using for example ultrafiltration or treated for longer-term preservation using any suitable preservation methodology. For example the chymosin preparation may be sterilized using methodologies such as filtration or  
5 ultrafiltration.

Optionally the chymosin preparation may be concentrated using for example ultrafiltration or treated for longer-term preservation using any suitable preservation methodology. For example the chymosin preparation may be sterilized using methodologies such as filtration or  
10 ultrafiltration.

The following non-limiting examples are illustrative of the present invention:

### EXAMPLES

#### EXAMPLE 1

15 Construction of a plant transformation vector comprising of a chimeric nucleic acid sequence containing *pre-pro-chymosin*.

A pro-chymosin gene was re-synthesized from the bovine pro-chymosin to reflect the plant-preferred codons (See Figure 1 and SEQ.ID.NOS.: 1 and 2). Amino acids 27 to 67 are the pro-peptide sequence  
20 and amino acids 68 to 390 are the mature chymosin polypeptide. A PR-S signal sequence was attached to the 5' end of the pro-chymosin gene by PCR fusion. The PRS sequence includes amino acids 1 to 26 in Figure 1. The pre-pro-chymosin DNA fragment was fused in between a phaseolin promoter and the phaseolin terminator derived from the common bean  
25 *Phaseolus vulgaris* Slightom et al (1983) Proc. Natl Acad Sc USA 80: 1897-1901). A complete sequence of the phaseolin promoter-preprochymosin-phaseolin terminator insert responsible for the expression of chymosin in plant seeds is shown in Figure 2 and SEQ.ID.NO.:3. This insert was cloned into the PstI-KpnI sites of vector  
30 pSBS2004 and pSBS3000 and resulted in plasmids pSBS2151 and pSBS2165 respectively. pSBS2004 is a derivative from the *Agrobacterium* binary plasmid pCGN1559 (MacBride and Summerfield, 1990, Plant Molec. Biol.

- 26 -

14 269-276) in which, the CAMV 35S promoter-neomycin phosphotransferase gene- tumor morphology large locus 3' antibiotic selection cassette of pCGN1559 was replaced with parsley ubiquitin promoter-phosphinothricin acyltransferase gene-parsley ubiquitin  
5 termination sequence to confer resistance to the herbicide glufosinate ammonium. pSBS3000 is a derivative from the *Agrobacterium* binary plasmid pPZP221 (Hajdukiewicz et al., 1994, Plant Molec. Biol. 25: 989-994). In pSBS3000, the CaMV35S promoter-gentamycin resistance gene-CAMV  
10 35S terminator of pPZP221 was replaced with parsley ubiquitin promoter-phosphinothricin acetyl transferase gene-parsley ubiquitin termination sequence to confer resistance to the herbicide glufosinate ammonium.

#### EXAMPLE 2

##### Generation of chymosin-expressing transgenic plants

15 Plasmids pSBS2151 and pSBS2165 were electroporated into *Agrobacterium* strain EHA101 (Hood, et al (1986) J Bacteriol 144: 732-743). *Agrobacterium* strain EHA101 (pSBS2151) was used to transform *Brassica napus*. The procedure for the transformation of *Brassica* has been essentially outlined in Moloney et al. (1989) Plant Cell Reports 8: 238-242,  
20 except phosphinothricin, at a concentration of 1 to 2 mg/L, was used as the selectable agent. *Agrobacterium* strain EHA101 (pSBS2165) was used to transform flax cv Mc Gregor. Flax transformation was performed essentially as described in Jordan and McHughen (1988) Plant cell reports 7: 281-284, except transgenic shoots were selected on 10  $\mu$ M  
25 L-phosphinothricine instead of kanamycin.

#### EXAMPLE 3

##### Expression levels of chymosin in *Brassica*

Physical characteristics of *Brassica napus* seed extracted chymosin were compared relative to commercially available bovine  
30 chymosin. The molecular weight of the two chymosin proteins was determined by gel electrophoresis on a 12% poly-acrylamide gel and Western blot analysis using a polyclonal rabbit antibody as shown in

- 27 -

Figure 3. Specified concentrations were loaded onto a 12% poly-acrylamide gel and transferred to a membrane. The membrane was probed with a polyclonal antibody raised against commercial available bovine chymosin and visualized using alkaline phosphatase. This polyclonal antibody is immunologically reactive with several bands in the transgenic seed extract. Bands of the same electroforetic mobility are found in the commercial bovine chymosin extract. This suggests that the majority of the pre-pro-chymosin in the seed extract has matured into chymosin. The lower molecular weight bands likely result from proteolytic digestion of the mature protein and the minor higher molecular weight bands could correspond to altered processed forms of either preprochymosin or prochymosin. The protein levels for chymosin in one of the Brassica plants analyzed is shown in Figure 3. Seeds were ground in water to make a seed extract and the protein concentration was determined as described in Bradford (1976) Anal. Biochem. 72: 248-254. Different concentrations of the same seed extract were electrophoresed on a gel along with a bovine derived chymosin standard loaded with known concentrations. Western blot analysis was performed with a polyclonal rabbit antibody and visualized using alkaline phosphatase. Quantitative densitometry was used to correlate the density of the 35.6 kDa band to the concentration of the protein by comparison with a standard curve derived from known concentrations of chymosin. Table 1 is a compilation of the data for the amount of chymosin in the identical seed extract of differing concentrations and resulting percent of expression. The slightly different levels reflect a standard error. Note that no data is provided for 4 µg and 8 µg of seed extract as the results exceeded the saturation range of the densitometer.

The biological activity of the plant (Brassica) derived chymosin was determined through the use of milk-clotting assays. In the milk-clotting assay, a diluted seed extract sample is added to a clotting substrate as described in (Tsuchiya et al. (1993) Appl. Microbiol. Biotechnol. 40: 327-332). Transgenic Brassica seeds had the ability to clot

- 28 -

milk whereas, seeds that were not transformed with the pro-chymosin gene were unable to clot milk.

#### EXAMPLE 4

##### Expression levels of chymosin in flax (*Linum usitatissimum*)

5 Transgenic flax plants containing the preprochymosin gene were analyzed for the presence of biologically active chymosin. The biological activity of the plant derived chymosin was determined through the use of milk-clotting assays. In the milk-clotting assay, a diluted flax seed extract sample is added to a clotting substrate as described in  
10 (Tsuchiya et al. (1993) Appl. Microbiol. Biotechnol. 40: 327-332). The clotting time or flake point is measured as the time it takes for the thin film of milk to break into visible particles. The concentration of chymosin in the seed extract is determined by comparing it to a linear standard curve plotted as clotting time in seconds against the chymosin concentration  
15 (Tsuchiya et al. (1993) Appl. Microbiol. Biotechnol. 40: 327-332). The chymosin concentration was first determined as a weight percentage of seed weight (=W%). The percentage chymosin as a percentage of total seed protein was calculated by using the formula (W/ percentage protein in dry seed) X 100. For flax the total amount of protein as a percentage of seed  
20 weight equals approximately 20 % (Gill, 1987, Linseed, Indian Council of Agricultural Research Publication). Wx5 equals the expression level of chymosin as a percentage of total seed protein. Figure 4 shows the expression levels of chymosin in transgenic flax seeds as a percentage of total protein for selected transformants.

#### 25 EXAMPLE 5

##### Purification of chymosin from transgenic *Brassica napus* seed

This example describes the laboratory-scale purification of chymosin from transgenic seed produced as described in example 2. Forty grams of transgenic *Brassica napus* seed containing recombinant chymosin  
30 was combined with 400 mls of a solution containing 250 mM NaCl. The mixture was ground using a polytron to produce a slurry releasing the chymosin into solution. This slurry was then centrifuged at

- 29 -

approximately 10,000 x g to separate it into three phases, a solid pellet phase of insoluble material, an upper phase of seed oil bodies and associated proteins and a middle aqueous phase containing the chymosin, soluble seed proteins and other soluble seed components. Following centrifugation, the aqueous phase was removed and clarified by filtration. The clarified extract was adjusted to a pH of 2.0 by addition of sulfuric acid and allowed to sit for several minutes and then readjusted to pH 5.6 with aqueous ammonia. The extract was then centrifuged at 10,000 x g to remove precipitated proteins and the soluble supernatant phase recovered.

10 The low pH-treated extract was diluted with water to a conductivity of approximately 9.5 mmohs and then loaded on to an anion exchange column containing approximately 30 mls of DEAE-cellulose previously equilibrated with 0.5% sodium benzoate, 0.379% NaCl, pH 5.6. After loading, the column was washed with approximately 200 mls of 0.5% sodium benzoate, 0.379% NaCl, pH 5.6 and then eluted with 110 mls of 0.5% sodium benzoate, 10% NaCl, pH 5.6. The eluate from the anion exchange step was loaded on to a gel filtration column containing G25 sephadex (Amersham-Pharmacia) equilibrated with 25 mM sodium phosphate, 1 M ammonium sulfate, pH 5.6. Fifty mls of the eluate from this column was passed through a 0.22 um filter and then loaded on to a hydrophobic interaction column containing 4.6 mls of butyl sepharose (Fast Flow, Amersham-Pharmacia) previously equilibrated with 25 mM sodium phosphate, 1 M ammonium sulfate, pH 5.6. After loading, the column was washed with 20 mls of 25 mM sodium phosphate, 1 M ammonium sulfate, pH 5.6 followed by 75 mls of 25 mM sodium phosphate, 0.55 M ammonium sulfate, pH 5.6. Purified chymosin was eluted from the column with 24 mls of 25 mM sodium phosphate, 0.1 M ammonium sulfate, pH 5.6. Figure 5 shows a SDS-polyacrylamide gel showing progressive purification of chymosin obtained from transgenic seeds of *Brassica napus* as described above. Lane 1, aqueous phase from total seed extract; lane 2 pH-treated extract; lane 3, DEAE-cellulose eluate; lane 4, purified chymosin eluted from butyl sepharose.

- 30 -

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and  
5 equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and  
10 individually indicated to be incorporated by reference in its entirety.

TABLE 1

mg of seed extract	0.5	1.0	2.0
ng of pro-chymosin in seed extract	21	47	88
level of expression (% of protein)	4.2	4.7	4.4
Average level of expression (% of protein )		4.43	



- 32 -

We Claim:

1. A method for the production of chymosin in a plant seed comprising:
  - a) introducing into a plant cell a chimeric nucleic acid  
5 sequence molecule comprising in the 5' to 3' direction of transcription:
    - 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
    - 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
    - 10 3) a third nucleic acid sequence capable of terminating transcription in said plant cell;
  - b) growing said plant cell into a mature plant capable of setting seed; and
  - c) obtaining seed from the mature plant wherein said seed  
15 contains chymosin.
2. The method according to claim 1 wherein said first nucleic sequence capable of regulating transcription in said plant cell is a seed-specific promoter.
3. The method according to claim 3 wherein said seed-specific  
20 promoter is a phaseolin promoter.
4. A method according to any one of claims 1 to 3 wherein at least 0.5% (w/w) of the total seed protein is chymosin.
5. The method according to any one of claims 1 to 4 wherein the second nucleic acid sequence encoding a chymosin polypeptide comprises  
25 a nucleic acid sequence encoding a chymosin pro-peptide, a nucleic acid sequence encoding a chymosin pre-peptide or a nucleic acid sequence encoding chymosin pre-pro-peptide.

- 33 -

6. The method according to claim 5 wherein the second nucleic acid sequence encoding a chymosin polypeptide further comprises a nucleic acid sequence encoding a plant signal sequence.
7. The method according to any one of claims 1 to 6 wherein the  
5 second nucleic acid sequence encoding a chymosin polypeptide further comprises a nucleic acid sequence encoding a plant signal sequence.
8. The method according to claim 7 wherein the plant signal sequence is a tobacco PR-S sequence.
9. The method according to claim 8 wherein the nucleic acid  
10 sequence encoding chymosin linked to a PR-S signal sequence comprises a nucleic acid sequence as in SEQ.ID.NO.:1.
10. The method according to any one of claims 1 to 9 wherein said third nucleic acid sequence is a phaseolin terminator.
11. The method according to any one of claims 1 to 9 wherein the  
15 chymosin is a mammalian chymosin obtainable from a bovine, sheep or goat source.
12. The method according to claim 5 wherein codon usage for said nucleic acid sequence encoding chymosin, chymosin pro-peptide, chymosin pre-peptide and chymosin pre-pro-peptide has been optimized  
20 for use in plants.
13. The method according to any one of claims 1 to 12 wherein said plant is selected from the group of plants consisting of soybean (*Glycine max*), rapeseed (*Brassica napus*, *Brassica campestris*), sunflower (*Helianthus annuus*), cotton (*Gossypium hirsutum*), corn (*Zea mays*),

- 34 -

tobacco (*Nicotiana tabacum*), alfalfa (*Medicago sativa*), wheat (*Triticum sp.*), barley (*Hordeum vulgare*), oats (*Avena sativa* L.), sorghum (*Sorghum bicolor*), Arabidopsis thaliana, potato (*Solanum sp.*), flax/linseed (*Linum usitatissimum*), safflower (*Carthamus tinctorius*), oil palm (*Eleais guineensis*), groundnut (*Arachis hypogaea*), Brazil nut (*Bertholletia excelsa*)  
5 coconut (*Cocus nucifera*), castor (*Ricinus communis*), coriander (*Coriandrum sativum*), squash (*Cucurbita maxima*), jojoba (*Simmondsia chinensis*) and rice (*Oryza sativa*).

14. The method according to any one of claims 1 to 13 wherein at  
10 least 1% (w/w) of said total seed protein is chymosin.

15. The method according to any one of claims 1 to 13 wherein at least 2% (w/w) of said total seed protein is chymosin.

16. The method according to any one of claims 1 to 13 wherein at least 4% (w/w) of said total seed protein is chymosin.

15 17. A method for the production of plant seeds containing at least 0.5% (w/w) chymosin in the total seed protein comprising:

(a) introducing into each of at least two plant cells a chimeric nucleic acid sequence molecule comprising in the 5' to 3' direction of transcription:

- 20
- 1) a first nucleic acid sequence capable of regulating transcription in said plant cell operatively linked to;
  - 2) a second nucleic acid sequence encoding a chymosin polypeptide operatively linked to;
  - 3) a third nucleic acid sequence capable of terminating  
25 transcription in said plant cell;

(b) growing each plant cell into a mature plant capable of setting seed;

(c) obtaining seed from each mature plant;

- 35 -

(d) detecting the levels of chymosin in the seed of each plant obtained in step (c) or in the seed of a plant generated from the seed of a plant obtained in step (c); and

(e) selecting plants that contain at least 0.5% (w/w) chymosin  
5 in the total seed protein.

18. A method according to any one of claims 1 to 16 further comprising (d) isolating said chymosin from said seed.

19. A method according to claim 18 wherein (d) isolating said chymosin from said seed comprises:

- 10 (i) crushing the plant seed to obtain crushed plant seed;  
(ii) contacting the crushed plant seed or a fraction thereof with a protein binding resin; and  
(iii) recovering chymosin from the protein binding resin.

20. A method according to claim 18 wherein (d) isolating said  
15 chymosin from said seed comprises:

- (i) crushing of the plant seed to obtain crushed plant seed;  
(ii) fractionating the crushed plant seed into an oil fraction, aqueous fraction and a fraction comprising insoluble material;  
20 (iii) contacting the aqueous fraction with a protein binding resin; and  
(iv) recovering the chymosin from the protein binding resin.

21. A method according to claim 19 wherein said protein binding resin is a hydrophobic interaction resin.

25 22. A method according to claim 20 wherein said protein binding resin is a hydrophobic interaction resin.

- 36 -

23. A method according to claim 21 or 22 further comprising using an ion exchange resin to further purify the chymosin.
24. Plant seed comprising at least 0.5% (w/w) heterologously expressed chymosin.
- 5 25. Plant seed prepared according to the method of any one of claims 1 to 23.
26. A plant capable of setting seed comprising at least 0.5% (w/w) of heterologously expressed chymosin.
27. A plant capable of setting seed prepared according to the  
10 method of any one of claims 1 to 23 .

1/8  
FIGURE 1

1	ATG	AAC	TTC	CTT	AAG	TCT	TTC	CCT	TTC	TAC	GCT	TTC	CTT	TGT	TTC	GGT	CAA	TAC	TTC	GTT	60
1	M	N	F	L	K	S	F	P	F	Y	A	F	L	C	F	G	Q	Y	F	V	20
60	GCT	GTT	ACT	CAC	GCT	GCT	GAG	ATC	ACC	CGC	ATT	CCT	CTC	TAC	AAA	GGT	AAG	TCT	CTC	CGT	120
21	A	V	T	H	A	A	E	I	T	R	I	P	L	Y	K	G	K	S	L	R	40
121	AAG	GCG	CTG	AAG	GAA	CAT	GGA	CTT	CTA	GAA	GAC	TTC	TTG	CAG	AAA	CAA	CAG	TAT	GGC	ATC	180
41	K	A	L	K	E	H	G	L	L	E	D	F	L	Q	K	Q	Q	Y	G	I	60
181	AGC	AGC	AAG	TAC	TCC	GGC	TTC	GGT	GAA	GTT	GCT	AGC	GTG	CCA	CTT	ACC	AAC	TAC	CTT	GAT	240
61	S	S	K	Y	S	G	F	G	E	V	A	S	V	P	L	T	N	Y	L	D	80
241	AGT	CAA	TAC	TTT	GGG	AAG	ATC	TAC	CTC	GGA	ACC	CCG	CCT	CAA	GAG	TTC	ACC	GTT	CTC	TTT	300
81	S	Q	Y	F	G	K	I	Y	L	G	T	P	P	Q	E	F	T	V	L	F	100
301	GAT	ACT	GGT	TCC	TCT	GAC	TTC	TGG	GTT	CCC	TCT	ATC	TAC	TGC	AAG	AGC	AAT	GCC	TGC	AAG	360
101	D	T	G	S	S	D	F	W	V	P	S	I	Y	C	K	S	N	A	C	K	120
361	AAC	CAC	CAA	AGA	TTC	GAT	CCG	AGA	AAG	TCG	TCC	ACC	TTC	CAG	AAC	TTA	GGC	AAA	CCC	TTG	420
121	N	H	Q	R	F	D	P	R	K	S	S	T	F	Q	N	L	G	K	P	L	140
420	TCT	ATA	CAC	TAC	GGT	ACA	GGT	AGC	ATG	CAA	GGA	ATC	TTA	GGC	TAT	GAT	ACC	GTC	ACT	GTC	480
141	S	I	H	Y	G	T	G	S	M	Q	G	I	L	G	Y	D	T	V	T	V	160
481	TCC	AAC	ATT	GTG	GAC	ATT	CAA	CAG	ACA	GTA	GGA	CTT	AGC	ACC	CAA	GAA	CCA	GGT	GAT	GTC	540
161	S	N	I	V	D	I	Q	Q	T	V	G	L	S	T	Q	E	P	G	D	V	180
541	TTC	ACC	TAT	GCA	GAA	TTC	GAT	GGC	ATC	CTT	GGT	ATG	GCA	TAC	CCA	TCG	CTC	GCG	TCA	GAG	600
181	F	T	Y	A	E	F	D	G	I	L	G	M	A	Y	P	S	L	A	S	E	200
601	TAC	TCG	ATA	CCT	GTG	TTT	GAC	AAC	ATG	ATG	AAC	CGA	CAC	CTA	GTA	GCT	CAA	GAC	TTG	TTC	660
201	Y	S	I	P	V	F	D	N	M	M	N	R	H	L	V	A	Q	D	L	F	220
661	TCG	GTT	TAC	ATG	GAC	AGG	AAT	GGC	CAG	GAG	AGC	ATG	CTC	ACG	CTT	GGA	GCT	ATT	GAT	CCA	720
221	S	V	Y	M	D	R	N	G	Q	E	S	M	L	T	L	G	A	I	D	P	240
721	TCC	TAC	TAC	ACA	GGA	TCT	CTT	CAC	TGG	GTT	CCA	GTC	ACT	GTG	CAG	CAG	TAC	TGG	CAA	TTC	780
241	S	Y	Y	T	G	S	L	H	W	V	P	V	T	V	Q	Q	Y	W	Q	F	260
781	ACT	GTG	GAC	AGT	GTC	ACC	ATC	AGC	GGT	GTG	GTT	GTT	GCA	TGT	GAA	GGT	GGA	TGT	CAA	GCT	840
261	T	V	D	S	V	T	I	S	G	V	V	V	A	C	E	G	G	C	Q	A	280
841	ATC	TTG	GAT	ACC	GGT	ACG	TCC	AAG	CTG	GTC	GGA	CCT	AGC	AGC	GAC	ATT	CTC	AAC	ATT	CAG	900
281	I	L	D	T	G	T	S	K	L	V	G	P	S	S	D	I	L	N	I	Q	300
901	CAA	GCT	ATT	GGA	GCC	ACA	CAG	AAC	CAG	TAC	GGT	GAG	TTT	GAC	ATA	GAT	TGC	GAC	AAC	CTT	960
301	Q	A	I	G	A	T	Q	N	Q	Y	G	E	F	D	I	D	C	D	N	L	320
961	AGC	TAC	ATG	CCT	ACA	GTT	GTC	TTT	GAG	ATC	AAC	GGC	AAG	ATG	TAC	CCA	CTG	ACC	CCC	TCC	1020
321	S	Y	M	P	T	V	V	F	E	I	N	G	K	M	Y	P	L	T	P	S	340
1021	GCC	TAT	ACC	AGC	CAG	GAT	CAA	GGG	TTC	TGC	ACC	AGT	GGA	TTC	CAG	AGT	GAG	AAC	CAT	TCC	1080
341	A	Y	T	S	Q	D	Q	G	F	C	T	S	G	F	Q	S	E	N	H	S	360

2/8

## FIGURE 1 cont'd

1081 CAG AAA TGG ATC TTG GGA GAT GTG TTC ATT CGT GAG TAC TAC AGC GTC TTT GAC AGG GCC 1140  
361 Q K W I L G D V F I R E Y Y S V F D R A 380

1141 AAC AAC CTC GTT GGG CTA GCT AAA GCA ATC TGA 1200  
381 N N L V G L A K A I \* 391

3/8

## FIGURE 2

1 ctgcaggaattcattgtactcccagtatcattatagtgaaagttttggctctctcgccggtgggtttttacctctattta 80  
81 aaggggttttccacctaaaaattctggtatcattctcactttacttgttactttaattttctcataatctttggttgaaat 160  
161 tatcacgcttccgcacacgatatccctacaaatttattatttggttaaacattttcaaacgcataaaaattttatgaagtc 240  
241 ccgtctatcttttaagttagtctaacattttcatattgaaatatataatttacttaatttttagcggttgtagaaagcataa 320  
321 agatttattcttattcttcttcttcatataaatgtttaatatataataaacaattctttaccttaagaaggatttcccat 400  
401 ttatatattttaaaaatatattttcaaatatttttcaaccacgttaaatctcataataataagttgtttcaaaagtaataa 480  
481 aatttaactccataatttttttattcgactgatcttaagcaacacccagtgacacaactagccatttttttctttgaat 560  
561 aaaaaaatccaattatcattgtattttttttatacaatgaaaattttcaccaacaatcatttgggtatttctgaagcaa 640  
641 gtcattgttatgcaaaattctataattcccatgtgacactacggaagtaactgaagatctgctttacatgcgagacacat 720  
721 cttctaaagtaattttaataatagttactatattcaagatttcataatatcaataactcaatattacttctaaaaaattaa 800  
801 ttagatataattaaaatattacttttttaattttaagtttaattgttgaattgtgactattgatttatttctactat 880  
881 gtttaaatgttttatagatagtttaagtaaatataagtaatgtagtagtgtagtggttagagtggtaccctaaaccataaac 960  
961 tataacatttatggtggactaattttcatatatttcttattgcttttaccttttcttggtatgtaagtcgtaactagaa 1040  
1041 ttacagtggtgttgcctatggcactctgtggtcttttggttcattgcatgggtcttgcgcaagaaaaagacaaagaacaaaga 1120  
1121 aaaaagacaaaacagagagacaaaacgcaatcacacaaccaactcaaatagtcactgggtgatcaagatcgccgctcc 1200  
1201 atgtatgtctaaatgccatgcaaagcaacacgtgcttaacatgcactttaaatggctcaccatctcaaccacacacaa 1280  
1281 acacattgccttttttcttcatcatcaccacaaccacctgtatatattcattctcttccgccacctcaatttcttctacttc 1360  
1361 aacacacgtcaacctgcatatgctgtcatcccatgccc aaatctccatgcatgttccaaccaccttctctcttatataa 1440  
1441 tacctataaataacctctaataatcactcacttctttcatcatccatccatccagagtactactactctactactataatac 1520  
1521 cccaaccaactcatattcaatactactctact ATG AAC TTC CTT AAG TCT TTC CCT TTC TAC GCT 1586  
1 M N F L K S F P F Y A 11  
1587 TTC CTT TGT TTC GGT CAA TAC TTC GTT GCT GTT ACT CAC GCT GCT GAG ATC ACC CGC ATT 1646  
12 F L C F G Q Y F V A V T H A A E I T R I 31  
1647 CCT CTC TAC AAA GGT AAG TCT CTC CGT AAG GCG CTG AAG GAA CAT GGA CTT CTA GAA GAC 1706  
32 P L Y K G K S L R K A L K E H G L L E D 51  
1707 TTC TTG CAG AAA CAA CAG TAT GGC ATC AGC AGC AAG TAC TCC GGC TTC GGT GAA GTT GCT 1766  
52 F L Q K Q Q Y G I S S K Y S G F G E V A 71



4/8

## FIGURE 2 cont'd

1767 AGC GTG CCA CTT ACC AAC TAC CTT GAT AGT CAA TAC TTT GGG AAG ATC TAC CTC GGA ACC 1826  
72 S V P L T N Y L D S Q Y F G K I Y L G T 91

1827 CCG CCT CAA GAG TTC ACC GTT CTC TTT GAT ACT GGT TCC TCT GAC TTC TGG GTT CCC TCT 1886  
92 P P Q E F T V L F D T G S S D F W V P S 111

1887 ATC TAC TGC AAG AGC AAT GCC TGC AAG AAC CAC CAA AGA TTC GAT CCG AGA AAG TCG TCC 1946  
112 I Y C K S N A C K N H Q R F D P R K S S 131

1947 ACC TTC CAG AAC TTA GGC AAA CCC TTG TCT ATA CAC TAC GGT ACA GGT AGC ATG CAA GGA 2006  
132 T F Q N L G K P L S I H Y G T G S M Q G 151

2007 ATC TTA GGC TAT GAT ACC GTC ACT GTC TCC AAC ATT GTG GAC ATT CAA CAG ACA GTA GGA 2066  
152 I L G Y D T V T V S N I V D I Q Q T V G 171

2067 CTT AGC ACC CAA GAA CCA GGT GAT GTC TTC ACC TAT GCA GAA TTC GAT GGC ATC CTT GGT 2126  
172 L S T Q E P G D V F T Y A E F D G I L G 191

2127 ATG GCA TAC CCA TCG CTC GCG TCA GAG TAC TCG ATA CCT GTG TTT GAC AAC ATG ATG AAC 2186  
192 M A Y P S L A S E Y S I P V F D N M M N 211

2187 CGA CAC CTA GTA GCT CAA GAC TTG TTC TCG GTT TAC ATG GAC AGG AAT GGC CAG GAG AGC 2246  
212 R H L V A Q D L F S V Y M D R N G Q E S 231

2247 ATG CTC ACG CTT GGA GCT ATT GAT CCA TCC TAC TAC ACA GGA TCT CTT CAC TGG GTT CCA 2306  
232 M L T L G A I D P S Y Y T G S L H W V P 251

2307 GTC ACT GTG CAG CAG TAC TGG CAA TTC ACT GTG GAC AGT GTC ACC ATC AGC GGT GTG GTT 2366  
252 V T V Q Q Y W Q F T V D S V T I S G V V 271

2367 GTT GCA TGT GAA GGT GGA TGT CAA GCT ATC TTG GAT ACC GGT ACG TCC AAG CTG GTC GGA 2426  
272 V A C E G G C Q A I L D T G T S K L V G 291

2427 CCT AGC AGC GAC ATT CTC AAC ATT CAG CAA GCT ATT GGA GCC ACA CAG AAC CAG TAC GGT 2486  
292 P S S D I L N I Q Q A I G A T Q N Q Y G 311

2487 GAG TTT GAC ATA GAT TGC GAC AAC CTT AGC TAC ATG CCT ACA GTT GTC TTT GAG ATC AAC 2546  
312 E F D I D C D N L S Y M P T V V F E I N 331

2547 GGC AAG ATG TAC CCA CTG ACC CCC TCC GCC TAT ACC AGC CAG GAT CAA GGG TTC TGC ACC 2606  
332 G K M Y P L T P S A Y T S Q D Q G F C T 351

2607 AGT GGA TTC CAG AGT GAG AAC CAT TCC CAG AAA TGG ATC TTG GGA GAT GTG TTC ATT CGT 2666  
352 S G F Q S E N H S Q K W I L G D V F I R 371

2667 GAG TAC TAC AGC GTC TTT GAC AGG GCC AAC AAC CTC GTT GGG CTA GCT AAA GCA ATC TGA 2726  
372 E Y Y S V F D R A N N L V G L A K A I \* 391

2727 agcttaataagtatgaactaaaatgcatgtaggtgtaagagctcatggagagcatggaatattgtatccgaccatgtaac 2806

5/8

## FIGURE 2 cont'd

2807 agtataataactgagctccatctcacttcttctatgaataaacaaggatgttatgatataattaacactctatctatgca 2886  
2887 ccttattgttctatgataaatcttctcttattattataaatcatctgaatcgtgacggcttatggaatgcttcaaatagt 2966  
2967 acaaaaacaatgtgtactataagacttttctaacaattctaacttttagcattgtgaacgagacataagtgttaagaaga 3046  
3047 cataacaattataatggaagaagtttgtctccatttatattatattatataactaccacttatgtattatattaggatgttaa 3126  
3127 ggagacataacaattataaagagagaagtttgtatccatttatattatataactaccatttatattataacttatcc 3206  
3207 acttatttaaatgtctttataagggtttgatccatgatatttctaatatttttagttgatatttatgaagggtactattt 3286  
3287 gaactctcttactctgtataaagggttgatcatccttaaagtgggtctatttaattttattgcttcttacagataaaaaa 3366  
3367 aaaattatgagttggtttgataaaatattgaaggattttaaataataataaataaataaacatataatatatgtatat 3446  
3447 aaattttattataatataacatttatctataaaaaagtaaatattgtcataaatctatacaatcgttttagccttgctggac 3526  
3527 gactctcaattattttaacgagagtaaacatatttgactttttgggtattttaacaaattattatttaacactatatgaaa 3606  
3607 ttttttttttttatcggcaaggaaataaaattaaattaggaggagacaatgggtgtgtcccaatccttatacaaccaacttc 3686  
3687 cacaggaaggtcaggtcggggacaacaaaaaacaggcaagggaatttttaatttgggtgtcttgtttgtctgcataa 3766  
3767 tttatgcagtaaaacactacacataacccttttagcagtagagcaatgggtgaccgtgtgcttagcttctttttattttat 3846  
3847 ttttttatcagcaaagaataaaataaaataaaatgagacacttcagggatgtttcaacccttatacaaaaccccaaaaaa 3926  
3927 agtttcttagcaccctaccaactaagggtacc 3957

6 / 8

# FIGURE 3






FIGURE 4

Expression of chymosin in plants



8 / 8  
**FIGURE 5**



1/8

## SEQUENCE LISTING

<110> van Rooijen, Gijs  
 Keon, Richard Glenn  
 Boothe, Joseph  
 Shen, Yin  
 SemBioSys Genetics Inc.

<120> Commercial Production of Chymosin in Plants

<130> 9369-152

<140>

<141>

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 1173

<212> DNA

<213> Bovine

<220>

<221> CDS

<222> (1)..(1173)

<400> 1

atg aac ttc ctt aag tct ttc cct ttc tac gct ttc ctt tgt ttc ggt	48
Met Asn Phe Leu Lys Ser Phe Pro Phe Tyr Ala Phe Leu Cys Phe Gly	
1 5 10 15	
caa tac ttc gtt gct gtt act cac gct gct gag atc acc cgc att cct	96
Gln Tyr Phe Val Ala Val Thr His Ala Ala Glu Ile Thr Arg Ile Pro	
20 25 30	
ctc tac aaa ggt aag tct ctc cgt aag gcg ctg aag gaa cat gga ctt	144
Leu Tyr Lys Gly Lys Ser Leu Arg Lys Ala Leu Lys Glu His Gly Leu	
35 40 45	
cta gaa gac ttc ttg cag aaa caa cag tat ggc atc agc agc aag tac	192
Leu Glu Asp Phe Leu Gln Lys Gln Gln Tyr Gly Ile Ser Ser Lys Tyr	
50 55 60	
tcc ggc ttc ggt gaa gtt gct agc gtg cca ctt acc aac tac ctt gat	240
Ser Gly Phe Gly Glu Val Ala Ser Val Pro Leu Thr Asn Tyr Leu Asp	
65 70 75 80	
agt caa tac ttt ggg aag atc tac ctc gga acc ccg cct caa gag ttc	288
Ser Gln Tyr Phe Gly Lys Ile Tyr Leu Gly Thr Pro Pro Gln Glu Phe	
85 90 95	
acc gtt ctc ttt gat act ggt tcc tct gac ttc tgg gtt ccc tct atc	336
Thr Val Leu Phe Asp Thr Gly Ser Ser Asp Phe Trp Val Pro Ser Ile	
100 105 110	
tac tgc aag agc aat gcc tgc aag aac cac caa aga ttc gat ccg aga	384
Tyr Cys Lys Ser Asn Ala Cys Lys Asn His Gln Arg Phe Asp Pro Arg	
115 120 125	
aag tcg tcc acc ttc cag aac tta ggc aaa ccc ttg tct ata cac tac	432
Lys Ser Ser Thr Phe Gln Asn Leu Gly Lys Pro Leu Ser Ile His Tyr	
130 135 140	

2/8

ggt aca ggt agc atg caa gga atc tta ggc tat gat acc gtc act gtc	480
Gly Thr Gly Ser Met Gln Gly Ile Leu Gly Tyr Asp Thr Val Thr Val	
145 150 155 160	
tcc aac att gtg gac att caa cag aca gta gga ctt agc acc caa gaa	528
Ser Asn Ile Val Asp Ile Gln Gln Thr Val Gly Leu Ser Thr Gln Glu	
165 170 175	
cca ggt gat gtc ttc acc tat gca gaa ttc gat ggc atc ctt ggt atg	576
Pro Gly Asp Val Phe Thr Tyr Ala Glu Phe Asp Gly Ile Leu Gly Met	
180 185 190	
gca tac cca tcg ctc gcg tca gag tac tcg ata cct gtg ttt gac aac	624
Ala Tyr Pro Ser Leu Ala Ser Glu Tyr Ser Ile Pro Val Phe Asp Asn	
195 200 205	
atg atg aac cga cac cta gta gct caa gac ttg ttc tcg gtt tac atg	672
Met Met Asn Arg His Leu Val Ala Gln Asp Leu Phe Ser Val Tyr Met	
210 215 220	
gac agg aat ggc cag gag agc atg ctc acg ctt gga gct att gat cca	720
Asp Arg Asn Gly Gln Glu Ser Met Leu Thr Leu Gly Ala Ile Asp Pro	
225 230 235 240	
tcc tac tac aca gga tct ctt cac tgg gtt cca gtc act gtg cag cag	768
Ser Tyr Tyr Thr Gly Ser Leu His Trp Val Pro Val Thr Val Gln Gln	
245 250 255	
tac tgg caa ttc act gtg gac agt gtc acc atc agc ggt gtg gtt gtt	816
Tyr Trp Gln Phe Thr Val Asp Ser Val Thr Ile Ser Gly Val Val Val	
260 265 270	
gca tgt gaa ggt gga tgt caa gct atc ttg gat acc ggt acg tcc aag	864
Ala Cys Glu Gly Gly Cys Gln Ala Ile Leu Asp Thr Gly Thr Ser Lys	
275 280 285	
ctg gtc gga cct agc agc gac att ctc aac att cag caa gct att gga	912
Leu Val Gly Pro Ser Ser Asp Ile Leu Asn Ile Gln Gln Ala Ile Gly	
290 295 300	
gcc aca cag aac cag tac ggt gag ttt gac ata gat tgc gac aac ctt	960
Ala Thr Gln Asn Gln Tyr Gly Glu Phe Asp Ile Asp Cys Asp Asn Leu	
305 310 315 320	
agc tac atg cct aca gtt gtc ttt gag atc aac ggc aag atg tac cca	1008
Ser Tyr Met Pro Thr Val Val Phe Glu Ile Asn Gly Lys Met Tyr Pro	
325 330 335	
ctg acc ccc tcc gcc tat acc agc cag gat caa ggg ttc tgc acc agt	1056
Leu Thr Pro Ser Ala Tyr Thr Ser Gln Asp Gln Gly Phe Cys Thr Ser	
340 345 350	
gga ttc cag agt gag aac cat tcc cag aaa tgg atc ttg gga gat gtg	1104
Gly Phe Gln Ser Glu Asn His Ser Gln Lys Trp Ile Leu Gly Asp Val	
355 360 365	
ttc att cgt gag tac tac agc gtc ttt gac agg gcc aac aac ctc gtt	1152
Phe Ile Arg Glu Tyr Tyr Ser Val Phe Asp Arg Ala Asn Asn Leu Val	
370 375 380	
ggg cta gct aaa gca atc tga	1173
Gly Leu Ala Lys Ala Ile	
385 390	

3/8

<210> 2  
 <211> 390  
 <212> PRT  
 <213> Bovine

<400> 2  
 Met Asn Phe Leu Lys Ser Phe Pro Phe Tyr Ala Phe Leu Cys Phe Gly  
   1                  5                  10                  15  
 Gln Tyr Phe Val Ala Val Thr His Ala Ala Glu Ile Thr Arg Ile Pro  
           20                  25                  30  
 Leu Tyr Lys Gly Lys Ser Leu Arg Lys Ala Leu Lys Glu His Gly Leu  
           35                  40                  45  
 Leu Glu Asp Phe Leu Gln Lys Gln Gln Tyr Gly Ile Ser Ser Lys Tyr  
           50                  55                  60  
 Ser Gly Phe Gly Glu Val Ala Ser Val Pro Leu Thr Asn Tyr Leu Asp  
           65                  70                  75                  80  
 Ser Gln Tyr Phe Gly Lys Ile Tyr Leu Gly Thr Pro Pro Gln Glu Phe  
                   85                  90                  95  
 Thr Val Leu Phe Asp Thr Gly Ser Ser Asp Phe Trp Val Pro Ser Ile  
           100                  105                  110  
 Tyr Cys Lys Ser Asn Ala Cys Lys Asn His Gln Arg Phe Asp Pro Arg  
           115                  120                  125  
 Lys Ser Ser Thr Phe Gln Asn Leu Gly Lys Pro Leu Ser Ile His Tyr  
           130                  135                  140  
 Gly Thr Gly Ser Met Gln Gly Ile Leu Gly Tyr Asp Thr Val Thr Val  
   145                  150                  155                  160  
 Ser Asn Ile Val Asp Ile Gln Gln Thr Val Gly Leu Ser Thr Gln Glu  
           165                  170                  175  
 Pro Gly Asp Val Phe Thr Tyr Ala Glu Phe Asp Gly Ile Leu Gly Met  
           180                  185                  190  
 Ala Tyr Pro Ser Leu Ala Ser Glu Tyr Ser Ile Pro Val Phe Asp Asn  
           195                  200                  205  
 Met Met Asn Arg His Leu Val Ala Gln Asp Leu Phe Ser Val Tyr Met  
   210                  215                  220  
 Asp Arg Asn Gly Gln Glu Ser Met Leu Thr Leu Gly Ala Ile Asp Pro  
   225                  230                  235                  240  
 Ser Tyr Tyr Thr Gly Ser Leu His Trp Val Pro Val Thr Val Gln Gln  
           245                  250                  255  
 Tyr Trp Gln Phe Thr Val Asp Ser Val Thr Ile Ser Gly Val Val Val  
           260                  265                  270  
 Ala Cys Glu Gly Gly Cys Gln Ala Ile Leu Asp Thr Gly Thr Ser Lys  
           275                  280                  285  
 Leu Val Gly Pro Ser Ser Asp Ile Leu Asn Ile Gln Gln Ala Ile Gly  
           290                  295                  300  
 Ala Thr Gln Asn Gln Tyr Gly Glu Phe Asp Ile Asp Cys Asp Asn Leu  
   305                  310                  315                  320



```

<400> 3
ctgcaggaat tcattgtact cccagtatca ttatagttaa agttttggct ctctcgccgg 60
tggttttttaa cctctattta aaggggtttt ccacctaaaa attctgggat cattctcact 120
ttacttggtta ctttaatttc tcataatcct tggttgaaat tatcacgctt ccgcacacga 180
tatccctaca aatttattat ttgttaaaca ttttcaaacc gcataaaatt ttatgaagtc 240
ccgtctatct ttaatgtagt ctaacatttt catattgaaa tatataattt acttaatttt 300
agcgttggta gaaagcataa agatttatct ttattcttct tcatataaat gtttaatata 360
caatataaac aaattcttta ccttaagaag gatttcccat tttatatttt aaaaatatat 420
ttatcaaata tttttcaacc acgtaaatct cataataata agttgtttca aaagtaataa 480
aatttaactc cataattttt ttattcgact gatcttaaag caacaccagc tgacacaact 540
agccattttt ttctttgaat aaaaaaatcc aattatcatt gtattttttt tatacaatga 600
aaatttcacc aaacaatcat ttgtggtatt tctgaagcaa gtcattgtat gcaaaattct 660
ataattccca ttgacacta cggaagtaac tgaagatctg cttttacatg cgagacacat 720
cttctaaaagt aattttaata atagttacta tattcaagat ttcatatatc aaatactcaa 780
tattacttct aaaaaattaa ttagatataa ttaaaatatt acttttttaa ttttaagttt 840
aattggtgaa ttgtgacta ttgatttatt attctactat gtttaaattg ttttatagat 900
agtttaaagt aaatataagt aatgtagtag agtgtagag tgttacccta aaccataaac 960
tataacattt atgggtggact aattttcata tatttcttat tgcttttacc ttttcttggg 1020
atgtaagtcc gtaactagaa ttacagtggg ttgccatggc actctgtggg cttttgggtc 1080

```





7/8

atactaccca tttatatatt atacttatcc acttatttaa tgtctttata aggtttgatc 3236  
 catgatattt ctaatatatt agttgatatg tatatgaaag ggtactattt gaactctctt 3296  
 actctgtata aaggttggat catccttaaa gtgggtctat ttaattttat tgcttcttac 3356  
 agataaaaaa aaaattatga gttggtttga taaaatattg aaggatttaa aataataata 3416  
 aataataaat aacatataat atatgtatat aaatttatta taatataaca tttatctata 3476  
 aaaaagtaaa tattgtcata aatctataca atcgttttagc cttgctggac gactctcaat 3536  
 tatttaaacg agagtaaaca tatttgactt tttggttatt taacaaatta ttattttaaca 3596  
 ctatatgaaa tttttttttt ttatcggcaa ggaaataaaa ttaaattagg agggacaatg 3656  
 gtgtgtccca atccttatac aaccaacttc cacaggaagg tcaggtcggg gacaacaaaa 3716  
 aaacaggcaa gggaaatttt ttaatttggg ttgtcttgtt tgctgcataa tttatgcagt 3776  
 aaaacactac acataaccct tttagcagta gagcaatggt tgaccgtgtg cttagcttct 3836  
 tttattttat ttttttatca gcaaagaata aataaaataa aatgagacac ttcagggatg 3896  
 tttcaaccct tatacaaaac cccaaaaaca agtttcctag caccctacca actaaggtac 3956  
 c 3957

<210> 4  
 <211> 390  
 <212> PRT  
 <213> Artificial Sequence

<400> 4  
 Met Asn Phe Leu Lys Ser Phe Pro Phe Tyr Ala Phe Leu Cys Phe Gly  
 1 5 10 15  
 Gln Tyr Phe Val Ala Val Thr His Ala Ala Glu Ile Thr Arg Ile Pro  
 20 25 30  
 Leu Tyr Lys Gly Lys Ser Leu Arg Lys Ala Leu Lys Glu His Gly Leu  
 35 40 45  
 Leu Glu Asp Phe Leu Gln Lys Gln Gln Tyr Gly Ile Ser Ser Lys Tyr  
 50 55 60  
 Ser Gly Phe Gly Glu Val Ala Ser Val Pro Leu Thr Asn Tyr Leu Asp  
 65 70 75 80  
 Ser Gln Tyr Phe Gly Lys Ile Tyr Leu Gly Thr Pro Pro Gln Glu Phe  
 85 90 95  
 Thr Val Leu Phe Asp Thr Gly Ser Ser Asp Phe Trp Val Pro Ser Ile  
 100 105 110  
 Tyr Cys Lys Ser Asn Ala Cys Lys Asn His Gln Arg Phe Asp Pro Arg  
 115 120 125  
 Lys Ser Ser Thr Phe Gln Asn Leu Gly Lys Pro Leu Ser Ile His Tyr  
 130 135 140  
 Gly Thr Gly Ser Met Gln Gly Ile Leu Gly Tyr Asp Thr Val Thr Val  
 145 150 155 160

8/8

Ser Asn Ile Val Asp Ile Gln Gln Thr Val Gly Leu Ser Thr Gln Glu  
 165 170 175  
 Pro Gly Asp Val Phe Thr Tyr Ala Glu Phe Asp Gly Ile Leu Gly Met  
 180 185 190  
 Ala Tyr Pro Ser Leu Ala Ser Glu Tyr Ser Ile Pro Val Phe Asp Asn  
 195 200 205  
 Met Met Asn Arg His Leu Val Ala Gln Asp Leu Phe Ser Val Tyr Met  
 210 215 220  
 Asp Arg Asn Gly Gln Glu Ser Met Leu Thr Leu Gly Ala Ile Asp Pro  
 225 230 235 240  
 Ser Tyr Tyr Thr Gly Ser Leu His Trp Val Pro Val Thr Val Gln Gln  
 245 250 255  
 Tyr Trp Gln Phe Thr Val Asp Ser Val Thr Ile Ser Gly Val Val Val  
 260 265 270  
 Ala Cys Glu Gly Gly Cys Gln Ala Ile Leu Asp Thr Gly Thr Ser Lys  
 275 280 285  
 Leu Val Gly Pro Ser Ser Asp Ile Leu Asn Ile Gln Gln Ala Ile Gly  
 290 295 300  
 Ala Thr Gln Asn Gln Tyr Gly Glu Phe Asp Ile Asp Cys Asp Asn Leu  
 305 310 315 320  
 Ser Tyr Met Pro Thr Val Val Phe Glu Ile Asn Gly Lys Met Tyr Pro  
 325 330 335  
 Leu Thr Pro Ser Ala Tyr Thr Ser Gln Asp Gln Gly Phe Cys Thr Ser  
 340 345 350  
 Gly Phe Gln Ser Glu Asn His Ser Gln Lys Trp Ile Leu Gly Asp Val  
 355 360 365  
 Phe Ile Arg Glu Tyr Tyr Ser Val Phe Asp Arg Ala Asn Asn Leu Val  
 370 375 380  
 Gly Leu Ala Lys Ala Ile  
 385 390

## INTERNATIONAL SEARCH REPORT

Intern:                      al Application No  
PCT/CA 00/00975

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/82 C12N15/12 C12N5/10 C12P21/02 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C12P A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, CHEM ABS Data, STRAND

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 49326 A (MOLONEY MAURICE ;ALCANTARA JOENEL (CA); ROOIJEN GIJS VAN (CA); SEM) 5 November 1998 (1998-11-05) * see pages 7-10 * the whole document ---	1-27
X	WO 92 01042 A (NOVONORDISK AS) 23 January 1992 (1992-01-23) cited in the application the whole document ---	1-27
X	DD 265 164 A (AKAD WISSENSCHAFTEN DDR) 22 February 1989 (1989-02-22) the whole document ---	1-27
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*A\* document member of the same patent family

Date of the actual completion of the international search

21 November 2000

Date of mailing of the international search report

28/11/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer \_\_\_\_\_

Hillenbrand, G

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 00/00975

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 18634 A (UNILEVER PLC ;UNILEVER NV (NL)) 29 October 1992 (1992-10-29) * see page 8, line 36 * the whole document -----	1-27
X	US 5 714 474 A (SIJMONS PETER CHRISTIAN ET AL) 3 February 1998 (1998-02-03) cited in the application * see claim 6 * the whole document -----	1-27

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/CA 00/00975

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9849326 A	05-11-1998	AU 7024098 A BR 9809416 A EP 0977873 A ZA 9803471 A	24-11-1998 13-06-2000 09-02-2000 27-10-1998
WO 9201042 A	23-01-1992	AU 8219291 A	04-02-1992
DD 265164 A	22-02-1989	NONE	
WO 9218634 A	29-10-1992	AU 669478 B AU 1468092 A CA 2106960 A EP 0580649 A JP 6506584 T US 5767363 A ZA 9202592 A	13-06-1996 17-11-1992 10-10-1992 02-02-1994 28-07-1994 16-06-1998 11-10-1993
US 5714474 A	03-02-1998	US 5543576 A AU 649447 B AU 7765691 A AU 632941 B AU 7776691 A CA 2054762 A CA 2056396 A EP 0449375 A EP 0449376 A HU 60767 A HU 215164 B HU 215260 B IL 97645 A JP 6501838 T JP 6502296 T KR 211308 B KR 225087 B WO 9114782 A WO 9114772 A NZ 237549 A NZ 237550 A PT 97110 A,B PT 97111 A RU 2129609 C RU 2128228 C	06-08-1996 26-05-1994 21-10-1991 14-01-1993 21-10-1991 24-09-1991 24-09-1991 02-10-1991 02-10-1991 28-10-1992 28-10-1998 30-11-1998 18-03-1997 03-03-1994 17-03-1994 02-08-1999 15-10-1999 03-10-1991 03-10-1991 25-06-1993 27-09-1993 29-11-1991 31-12-1991 27-04-1999 27-03-1999